Published in New England Journal of Medicine · View the paper (DOI)
A randomized, placebo-controlled trial found finerenone improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. The drug also showed benefits regardless of the ejection fraction and even in patients on other approved therapies.
Coverage from 2 institutions